• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较实效研究的良好研究实践:利用二次数据源提高非随机治疗效果研究中因果推断的分析方法:ISPOR 回顾性数据库分析良好研究实践工作组报告--第三部分。

Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.

机构信息

College of Pharmacy, Department of Clinical Sciences and Administration, University of Houston, Houston, TX 77030, USA.

出版信息

Value Health. 2009 Nov-Dec;12(8):1062-73. doi: 10.1111/j.1524-4733.2009.00602.x. Epub 2009 Sep 29.

DOI:10.1111/j.1524-4733.2009.00602.x
PMID:19793071
Abstract

OBJECTIVES

Most contemporary epidemiologic studies require complex analytical methods to adjust for bias and confounding. New methods are constantly being developed, and older more established methods are yet appropriate. Careful application of statistical analysis techniques can improve causal inference of comparative treatment effects from nonrandomized studies using secondary databases. A Task Force was formed to offer a review of the more recent developments in statistical control of confounding.

METHODS

The Task Force was commissioned and a chair was selected by the ISPOR Board of Directors in October 2007. This Report, the third in this issue of the journal, addressed methods to improve causal inference of treatment effects for nonrandomized studies.

RESULTS

The Task Force Report recommends general analytic techniques and specific best practices where consensus is reached including: use of stratification analysis before multivariable modeling, multivariable regression including model performance and diagnostic testing, propensity scoring, instrumental variable, and structural modeling techniques including marginal structural models, where appropriate for secondary data. Sensitivity analyses and discussion of extent of residual confounding are discussed.

CONCLUSIONS

Valid findings of causal therapeutic benefits can be produced from nonrandomized studies using an array of state-of-the-art analytic techniques. Improving the quality and uniformity of these studies will improve the value to patients, physicians, and policymakers worldwide.

摘要

目的

大多数当代流行病学研究需要复杂的分析方法来调整偏差和混杂。新方法不断被开发出来,而更古老、更成熟的方法仍然适用。仔细应用统计分析技术可以提高使用二级数据库的非随机研究中对比较治疗效果的因果推断。一个工作组成立,旨在对混杂控制的更近期统计方法发展进行综述。

方法

该工作组由 ISPOR 董事会于 2007 年 10 月委托并任命主席。本报告是该期刊的第三期,讨论了改善非随机研究中治疗效果因果推断的方法。

结果

工作组报告建议了一般分析技术和特定的最佳实践,在达成共识的地方包括:在多变量建模之前使用分层分析、包括模型性能和诊断测试的多变量回归、倾向评分、工具变量和结构建模技术,包括适当的二次数据的边缘结构模型。还讨论了敏感性分析和残余混杂程度的讨论。

结论

使用一系列最先进的分析技术,可以从非随机研究中得出治疗效果的有效因果发现。提高这些研究的质量和一致性将提高对全球患者、医生和政策制定者的价值。

相似文献

1
Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III.比较实效研究的良好研究实践:利用二次数据源提高非随机治疗效果研究中因果推断的分析方法:ISPOR 回顾性数据库分析良好研究实践工作组报告--第三部分。
Value Health. 2009 Nov-Dec;12(8):1062-73. doi: 10.1111/j.1524-4733.2009.00602.x. Epub 2009 Sep 29.
2
Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.比较疗效研究的良好研究实践:利用二次数据源设计非随机治疗效果研究中减轻偏倚和混杂的方法:国际药物经济学和结果研究学会回顾性数据库分析良好研究实践工作组报告--第二部分。
Value Health. 2009 Nov-Dec;12(8):1053-61. doi: 10.1111/j.1524-4733.2009.00601.x. Epub 2009 Sep 10.
3
Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.比较有效性研究的良好研究实践:使用二次数据源定义、报告和解释治疗效果的非随机研究:ISPOR 回顾性数据库分析良好研究实践工作组报告--第一部分。
Value Health. 2009 Nov-Dec;12(8):1044-52. doi: 10.1111/j.1524-4733.2009.00600.x. Epub 2009 Sep 29.
4
The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.ISPOR 成本效益研究质量改进良好实践工作组报告。
Value Health. 2009 Nov-Dec;12(8):1086-99. doi: 10.1111/j.1524-4733.2009.00605.x. Epub 2009 Sep 10.
5
Comparative effectiveness research: guidelines for good practices are just the beginning.比较效果研究:良好实践指南仅仅是个开始。
Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1):51-7. doi: 10.1586/erp.10.93.
6
Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.预算影响分析良好实践原则:ISPOR良好研究实践特别工作组——预算影响分析报告
Value Health. 2007 Sep-Oct;10(5):336-47. doi: 10.1111/j.1524-4733.2007.00187.x.
7
Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.前瞻性观察性研究评估比较有效性:ISPOR 良好研究实践工作组报告。
Value Health. 2012 Mar-Apr;15(2):217-30. doi: 10.1016/j.jval.2011.12.010.
8
Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.与临床试验同时进行成本效益分析的良好研究实践:药物经济学与结果研究协会随机对照试验-成本效益分析特别工作组报告
Value Health. 2005 Sep-Oct;8(5):521-33. doi: 10.1111/j.1524-4733.2005.00045.x.
9
Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.医疗保健评估中决策分析建模的良好实践原则:ISPOR良好研究实践——建模研究特别工作组报告
Value Health. 2003 Jan-Feb;6(1):9-17. doi: 10.1046/j.1524-4733.2003.00234.x.
10
Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III.从管理式医疗角度评估药物成本效果分析的药物成本测量良好研究实践:ISPOR 药物成本工作组报告——第三部分。
Value Health. 2010 Jan-Feb;13(1):14-7. doi: 10.1111/j.1524-4733.2009.00661.x. Epub 2009 Oct 26.

引用本文的文献

1
[Comparing the effectiveness of multiple dynamic treatment strategies using target trial emulation].[使用目标试验模拟比较多种动态治疗策略的有效性]
Pravent Gesundh. 2023 Jun 12:1-11. doi: 10.1007/s11553-023-01033-8.
2
Real-world evidence in gynecologic cancers presented at key oncology conferences in the United States: Distribution and factors related to high-tier acceptance.在美国主要肿瘤学会议上展示的妇科癌症真实世界证据:与高级别接受度相关的分布及因素
PLoS One. 2025 Apr 22;20(4):e0321654. doi: 10.1371/journal.pone.0321654. eCollection 2025.
3
Transparency in the secondary use of health data: assessing the status quo of guidance and best practices.
健康数据二次使用中的透明度:评估指南和最佳实践的现状
R Soc Open Sci. 2025 Mar 26;12(3):241364. doi: 10.1098/rsos.241364. eCollection 2025 Mar.
4
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study.医疗保险患者非酒精性脂肪性肝炎疾病进展相关成本:一项回顾性队列研究。
J Comp Eff Res. 2024 Dec;13(12):e240096. doi: 10.57264/cer-2024-0096. Epub 2024 Nov 22.
5
Incorporating healthcare access and equity in economic evaluations: a scoping review of guidelines.将医疗保健可及性和公平性纳入经济评估:指南的范围综述。
Int J Technol Assess Health Care. 2024 Nov 18;40(1):e59. doi: 10.1017/S0266462324000618.
6
Cost-effectiveness of a multidimensional post-discharge disease management program for heart failure patients-economic evaluation along a one-year observation period.多维度出院后疾病管理方案对心力衰竭患者的成本效益:为期一年的观察期内的经济学评价。
Clin Res Cardiol. 2024 Aug;113(8):1232-1241. doi: 10.1007/s00392-024-02395-5. Epub 2024 Feb 14.
7
Treatment with psychostimulants and atomoxetine in people with psychotic disorders: reassessing the risk of clinical deterioration in a real-world setting.在精神病患者中使用精神兴奋剂和托莫西汀治疗:在真实环境中重新评估临床恶化的风险。
Br J Psychiatry. 2024 Mar;224(3):98-105. doi: 10.1192/bjp.2023.149.
8
Chronic Low Back Pain with and without Concomitant Osteoarthritis: A Retrospective, Longitudinal Cohort Study of Patients in England.慢性下背痛伴或不伴骨关节炎:英格兰患者回顾性纵向队列研究。
Int J Clin Pract. 2023 Nov 9;2023:5105810. doi: 10.1155/2023/5105810. eCollection 2023.
9
Association of SGLT-2 Inhibitors With Treatment Satisfaction and Diabetes-Specific and General Health Status in Adults With Cardiovascular Disease and Type 2 Diabetes.钠-葡萄糖共转运蛋白 2(SGLT-2)抑制剂与伴有心血管疾病和 2 型糖尿病的成年人的治疗满意度以及糖尿病特异性和一般健康状况的相关性。
J Am Heart Assoc. 2023 Sep 5;12(17):e029058. doi: 10.1161/JAHA.122.029058. Epub 2023 Sep 1.
10
Health economic impact of moderate-to-severe chronic pain associated with osteoarthritis in England: a retrospective analysis of linked primary and secondary care data.英格兰与骨关节炎相关的中重度慢性疼痛的健康经济影响:基于初级和二级保健数据的回顾性分析。
BMJ Open. 2023 Jul 12;13(7):e067545. doi: 10.1136/bmjopen-2022-067545.